Synonyms: ARRY502 | example 237, enantiomer 1 [WO2009158426A1]
Compound class:
Synthetic organic
Comment: ARRY-502 is an oral, potent and selective prostaglandin D2 receptor 2 (DP2) antagonist. It is the (4S) enantiomer of one of the chemical structures (example 237) claimed in Array Biopharma's patent WO2009158426A1
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Burgess LE, Clark CT, Cook A, Corrette CP, Delise RK, Doherty GA, Hunt KW, Romoff T. (2009)
6-substituted phenoxychroman carboxylic acid derivatives. Patent number: WO2009158426A1. Assignee: Array Biopharma Inc.. Priority date: 25/06/2008. Publication date: 30/12/2009. |
2. Sulaiman I, Lim JC, Soo HL, Stanslas J. (2016)
Molecularly targeted therapies for asthma: Current development, challenges and potential clinical translation. Pulm Pharmacol Ther, 40: 52-68. [PMID:27453494] |